IMMX · Immix Biopharma, Inc.

Summary

Immix Biopharma, Inc. entered into Amendment No. 1 to its At The Market Offering Agreement dated June 3, 2025, with Citizens JMP Securities, LLC on March 25, 2026, permitting the Company to offer and sell up to $100,000,000 of common stock through the sales agent in an at-the-market offering. The amendment aligns with the Company's Form S-3 registration statement (File No. 333-292665) and includes a 3.0% commission and expense reimbursement up to $50,000.

Key takeaways

• Entered Amendment No. 1 on March 25, 2026 to Sales Agreement dated June 3, 2025
• Aggregate offering price increased to up to $100,000,000 of common stock (par value $0.0001)
• Citizens JMP Securities, LLC as sales agent using commercially reasonable efforts
• Sales agent commission of 3.0% of gross sales proceeds
• Reimbursement of specified expenses up to $50,000
• Legal opinion on validity of shares issued by Blank Rome LLP (Exhibit 5.1)